These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
983 related articles for article (PubMed ID: 23679331)
1. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331 [TBL] [Abstract][Full Text] [Related]
2. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA Oncology; 2013; 84(3):158-65. PubMed ID: 23296063 [TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889 [TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151 [TBL] [Abstract][Full Text] [Related]
5. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437 [TBL] [Abstract][Full Text] [Related]
6. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Hsiao SM; Chen CA; Lin HH; Hsieh CY; Wei LH Gynecol Oncol; 2009 Jan; 112(1):35-9. PubMed ID: 18977021 [TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin. Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640 [TBL] [Abstract][Full Text] [Related]
9. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190 [TBL] [Abstract][Full Text] [Related]
10. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma. Suprasert P; Cheewakriangkrai C; Manopunya M Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817 [TBL] [Abstract][Full Text] [Related]
11. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer. Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657 [TBL] [Abstract][Full Text] [Related]
14. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114 [TBL] [Abstract][Full Text] [Related]
15. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048 [TBL] [Abstract][Full Text] [Related]
17. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285 [TBL] [Abstract][Full Text] [Related]
18. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study. Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523 [TBL] [Abstract][Full Text] [Related]
19. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044 [TBL] [Abstract][Full Text] [Related]
20. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer]. Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]